Scleroderma: a treatable disease

Many effective treatments for scleroderma have emerged in recent years, including bosentan, an endothelin receptor antagonist, and epoprostenol, a prostacyclin, both of which target vasoconstriction. Cyclophosphamide may soon be proven effective against interstitial lung disease.

Saved in:
Bibliographic Details
Published inCleveland Clinic journal of medicine Vol. 70; no. 11; p. 954
Main Author Korn, Joseph H
Format Journal Article
LanguageEnglish
Published United States 01.11.2003
Subjects
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Antihypertensive Agents - therapeutic use
Bosentan
Humans
Pulmonary Fibrosis - etiology
Scleroderma, Systemic - complications
Scleroderma, Systemic - physiopathology
Scleroderma, Systemic - therapy
Sulfonamides - therapeutic use
Online AccessGet full text

Cover

More Information
Summary:Many effective treatments for scleroderma have emerged in recent years, including bosentan, an endothelin receptor antagonist, and epoprostenol, a prostacyclin, both of which target vasoconstriction. Cyclophosphamide may soon be proven effective against interstitial lung disease.
ISSN:0891-1150
1939-2869
DOI:10.3949/ccjm.70.11.954